Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Clinical trial NCT02834013 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02834013
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acinar Cell Carcinoma Adenoid Cystic Carcinoma Adrenal Cortical Carcinoma Adrenal Gland Pheochromocytoma Anal Canal Neuroendocrine Carcinoma Anal Canal Undifferentiated Carcinoma Angiosarcoma Apocrine Neoplasm Appendix Mucinous Adenocarcinoma Bartholin Gland Transitional Cell Carcinoma Basal Cell Carcinoma Bladder Adenocarcinoma

Start date: 2017-01-30
Primary completion: 2026-05-01
Enrollment: 798

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.